Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen

Wednesday, April 24, 2019

UroGen Pharma Ltd., a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an agreement with Janssen Research & Development, LLC (Janssen) to conduct an early-stage feasibility evaluation in a therapeutic area of mutual interest. UroGen and Janssen will each conduct certain activities under the terms of the agreement.

“We are excited to enter into this agreement with Janssen, an industry leader with a history of developing transformative therapies,” said Liz Barrett, President and Chief Executive Officer of UroGen. “We maintain a strong commitment to bringing innovative treatments to patients in areas of unmet need.”

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024